With tavapadon demonstrating a significant increase in total 'on' time without troublesome dyskinesia compared to placebo in the TEMPO-3 trial, how might this impact the daily lives of Parkinson's patients, particularly in terms of functional independence and quality of life?

Could you elaborate on the specific mechanisms through which tavapadon selectively activates D1/D5 dopamine receptors, and how this targeted action might contribute to its favorable safety profile compared to existing treatments?

Considering the results of the TEMPO-3 trial, what insights can we gain about tavapadon's potential to address the unmet needs of Parkinson's patients, particularly in terms of managing motor fluctuations and enhancing treatment efficacy over the long term?

In the context of adjunctive therapy to levodopa, how do the findings from the TEMPO-3 trial position tavapadon relative to other treatment options currently available for Parkinson's disease? Are there specific patient subgroups that may benefit most from this novel approach?

Given the progressive nature of Parkinson's disease, how might tavapadon's once-daily dosing regimen contribute to treatment adherence and overall disease management, particularly in comparison to existing therapies with more frequent dosing requirements?

In light of the statistically significant reduction in 'off' time observed with tavapadon in the TEMPO-3 trial, what implications does this have for mitigating the motor fluctuations and unpredictable symptomatology that often pose challenges in Parkinson's management?

Could you discuss the safety profile of tavapadon as evidenced by the TEMPO-3 trial, particularly in terms of the nature and frequency of adverse events reported? How might these findings inform clinical decision-making and patient counseling regarding treatment initiation?

Looking ahead, how do you envision tavapadon's role evolving in the landscape of Parkinson's disease treatment, especially considering the forthcoming data from the Phase 3 monotherapy trials (TEMPO-1 and TEMPO-2) and the potential implications for both clinicians and patients"